A citation-based method for searching scientific literature

N Avril, M Menzel, J Dose, M Schelling, W Weber, F Jänicke, W Nathrath, M Schwaiger. J Nucl Med 2001
Times Cited: 305







List of co-cited articles
615 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Can fluorine-18 fluoroestradiol positron emission tomography-computed tomography demonstrate the heterogeneity of breast cancer in vivo?
Zhongyi Yang, Yifei Sun, Yongping Zhang, Jing Xue, Mingwei Wang, Wei Shi, Beiling Zhu, Silong Hu, Zhifeng Yao, Herong Pan,[...]. Clin Breast Cancer 2013
19
15

Feasibility study of FDG PET as an indicator of early response to aromatase inhibitors and trastuzumab in a heterogeneous group of breast cancer patients.
Brenda F Kurland, Vijayakrishna K Gadi, Jennifer M Specht, Kimberly H Allison, Robert B Livingston, Eve T Rodler, Lanell M Peterson, Erin K Schubert, Xiaoyu Chai, David A Mankoff,[...]. EJNMMI Res 2012
27
11

Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer.
Mary L Gemignani, Sujata Patil, Venkatraman E Seshan, Michelle Sampson, John L Humm, Jason S Lewis, Edi Brogi, Steven M Larson, Monica Morrow, Neeta Pandit-Taskar. J Nucl Med 2013
42
7


18F-FDG PET-CT imaging in the neoadjuvant setting for stages II-III breast cancer: association of loco‑regional SUVmax with classical prognostic factors.
M García García-Esquinas, J A García-Sáenz, J Arrazola García, M Enrique Fuentes Ferrer, V Furió, C Rodriguez Rey, J M Román, J L Carreras Delgado. Q J Nucl Med Mol Imaging 2014
14
21

18F-fluorodeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT) imaging in the staging and prognosis of inflammatory breast cancer.
Jean-Louis Alberini, Florence Lerebours, Myriam Wartski, Emmanuelle Fourme, Elise Le Stanc, E Gontier, O Madar, P Cherel, A P Pecking. Cancer 2009
73
4


Fluoroestradiol positron emission tomography reveals differences in pharmacodynamics of aromatase inhibitors, tamoxifen, and fulvestrant in patients with metastatic breast cancer.
Hannah M Linden, Brenda F Kurland, Lanell M Peterson, Erin K Schubert, Julie R Gralow, Jennifer M Specht, Georgiana K Ellis, Thomas J Lawton, Robert B Livingston, Philip H Petra,[...]. Clin Cancer Res 2011
84
3

Prognostic value of quantitative fluorodeoxyglucose measurements in newly diagnosed metastatic breast cancer.
Gary A Ulaner, Anne Eaton, Patrick G Morris, Joshua Lilienstein, Komal Jhaveri, Sujata Patil, Maurizio Fazio, Steven Larson, Clifford A Hudis, Maxine S Jochelson. Cancer Med 2013
36
8

Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update.
Antonio C Wolff, M Elizabeth H Hammond, David G Hicks, Mitch Dowsett, Lisa M McShane, Kimberly H Allison, Donald C Allred, John M S Bartlett, Michael Bilous, Patrick Fitzgibbons,[...]. J Clin Oncol 2013
3


Bone imaging in metastatic breast cancer.
Tsuyoshi Hamaoka, John E Madewell, Donald A Podoloff, Gabriel N Hortobagyi, Naoto T Ueno. J Clin Oncol 2004
357
3

Pitfalls of FDG-PET for the diagnosis of osteoblastic bone metastases in patients with breast cancer.
Takako Nakai, Chio Okuyama, Takao Kubota, Kei Yamada, Yo Ushijima, Keiko Taniike, Takako Suzuki, Tsunehiko Nishimura. Eur J Nucl Med Mol Imaging 2005
150
3

Bone metastases in patients with metastatic breast cancer: morphologic and metabolic monitoring of response to systemic therapy with integrated PET/CT.
Ukihide Tateishi, Cristina Gamez, Shaheenah Dawood, Henry W D Yeung, Massimo Cristofanilli, Homer A Macapinlac. Radiology 2008
129
3

Integrated positron emission tomography/computed tomography may render bone scintigraphy unnecessary to investigate suspected metastatic breast cancer.
Patrick G Morris, Colleen Lynch, John N Feeney, Sujata Patil, Jane Howard, Steven M Larson, Maura Dickler, Clifford A Hudis, Maxine Jochelson, Heather L McArthur. J Clin Oncol 2010
79
3

Biologic correlation between glucose transporters, hexokinase-II, Ki-67 and FDG uptake in malignant melanoma.
Seok Gun Park, Jai Hyuen Lee, Won Ae Lee, Kang Min Han. Nucl Med Biol 2012
39
7

Metastatic lobular carcinoma of the breast: patterns of spread in the chest, abdomen, and pelvis on CT.
C B Winston, O Hadar, J B Teitcher, J F Caravelli, N T Sklarin, D M Panicek, L Liberman. AJR Am J Roentgenol 2000
92
3

Frequency and etiology of unexplained bilateral hydronephrosis in patients with breast cancer: results of a longitudinal CT study.
Ari J Kane, Zhen J Wang, Aliya Qayyum, Benjamin M Yeh, Emily M Webb, Fergus V Coakley. Clin Imaging 2012
5
60

Intratumoral metabolic heterogeneity of cervical cancer.
Elizabeth A Kidd, Perry W Grigsby. Clin Cancer Res 2008
122
3

Early prediction of response to chemotherapy and survival in malignant pleural mesothelioma using a novel semiautomated 3-dimensional volume-based analysis of serial 18F-FDG PET scans.
Roslyn J Francis, Michael J Byrne, Agatha A van der Schaaf, Jan A Boucek, Anna K Nowak, Michael Phillips, Richard Price, Andrew P Patrikeos, A William Musk, Michael J Millward. J Nucl Med 2007
131
3


Expression of glucose transporters in human pancreatic tumors compared with increased FDG accumulation in PET study.
T Higashi, N Tamaki, T Honda, T Torizuka, T Kimura, T Inokuma, G Ohshio, R Hosotani, M Imamura, J Konishi. J Nucl Med 1997
138
3

Differential subcellular distribution of glucose transporters GLUT1-6 and GLUT9 in human cancer: ultrastructural localization of GLUT1 and GLUT5 in breast tumor tissues.
Alejandro Godoy, Viviana Ulloa, Federico Rodríguez, Karin Reinicke, Alejandro J Yañez, María de los Angeles García, Rodolfo A Medina, Mónica Carrasco, Sofía Barberis, Tamara Castro,[...]. J Cell Physiol 2006
165
3

Expression of the fructose transporter GLUT5 in human breast cancer.
S P Zamora-León, D W Golde, I I Concha, C I Rivas, F Delgado-López, J Baselga, F Nualart, J C Vera. Proc Natl Acad Sci U S A 1996
135
3


18F-FDG uptake in squamous cell carcinoma of the cervix is correlated with glucose transporter 1 expression.
Tzu-Chen Yen, Lai-Chu See, Chyong-Huey Lai, Chou Wu Yah-Huei, Koon-Kwan Ng, Shih-Ya Ma, Wuu-Jyh Lin, Jenn-Tzong Chen, Wen-Jie Chen, Chiung-Ru Lai,[...]. J Nucl Med 2004
95
3

GLUT2 is a high affinity glucosamine transporter.
Marc Uldry, Mark Ibberson, Masaya Hosokawa, Bernard Thorens. FEBS Lett 2002
193
3

Differential expression of GLUT12 in breast cancer and normal breast tissue.
Suzanne Rogers, Susan E Docherty, John L Slavin, Michael A Henderson, James D Best. Cancer Lett 2003
58
5

Correlation of GLUT-1 overexpression, tumor size, and depth of invasion with 18F-2-fluoro-2-deoxy-D-glucose uptake by positron emission tomography in colorectal cancer.
Jinyu Gu, Hirofumi Yamamoto, Hiroki Fukunaga, Katsuki Danno, Ichiro Takemasa, Masataka Ikeda, Mitsuaki Tatsumi, Mitsugu Sekimoto, Jun Hatazawa, Tsunehiko Nishimura,[...]. Dig Dis Sci 2006
64
4

Glucose transporters in the 21st Century.
Bernard Thorens, Mike Mueckler. Am J Physiol Endocrinol Metab 2010
512
3

GLUT1 expression in human breast carcinoma: correlation with known prognostic markers.
M Younes, R W Brown, D R Mody, L Fernandez, R Laucirica. Anticancer Res 1995
175
3

Integrated contrast-enhanced diagnostic whole-body PET/CT as a first-line restaging modality in patients with suspected metastatic recurrence of breast cancer.
Albert Dirisamer, Benjamin S Halpern, Daniel Flöry, Florian Wolf, Mohsen Beheshti, Marius E Mayerhoefer, Werner Langsteger. Eur J Radiol 2010
46
6

Role of 2-[18F]-fluorodeoxyglucose (FDG) positron emission tomography (PET) in the early assessment of response to chemotherapy in metastatic breast cancer patients.
A Gennari, S Donati, B Salvadori, A Giorgetti, P A Salvadori, O Sorace, G Puccini, P Pisani, M Poli, D Dani,[...]. Clin Breast Cancer 2000
59
5

Breast cancer detection using high-resolution breast PET compared to whole-body PET or PET/CT.
Judith E Kalinyak, Wendie A Berg, Kathy Schilling, Kathleen S Madsen, Deepa Narayanan, Marie Tartar. Eur J Nucl Med Mol Imaging 2014
54
5

Pilot study of the utility of the synthetic PET amino-acid radiotracer anti-1-amino-3-[(18)F]fluorocyclobutane-1-carboxylic acid for the noninvasive imaging of pulmonary lesions.
Rianot Amzat, Pooneh Taleghani, Daniel L Miller, Jonathan J Beitler, Leah M Bellamy, Jonathon A Nye, Weiping Yu, Bital Savir-Baruch, Adeboye O Osunkoya, Zhengjia Chen,[...]. Mol Imaging Biol 2013
23
13

Synthesis and evaluation of [18F]1-amino-3-fluorocyclobutane-1-carboxylic acid to image brain tumors.
T M Shoup, J Olson, J M Hoffman, J Votaw, D Eshima, L Eshima, V M Camp, M Stabin, D Votaw, M M Goodman. J Nucl Med 1999
145
3

Quantitation in positron emission computed tomography: 1. Effect of object size.
E J Hoffman, S C Huang, M E Phelps. J Comput Assist Tomogr 1979
971
3

Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose.
N Avril, J Dose, F Jänicke, S Bense, S Ziegler, C Laubenbacher, W Römer, H Pache, M Herz, B Allgayer,[...]. J Clin Oncol 1996
190
3

Thoracic staging in lung cancer: prospective comparison of 18F-FDG PET/MR imaging and 18F-FDG PET/CT.
Philipp Heusch, Christian Buchbender, Jens Köhler, Felix Nensa, Thomas Gauler, Benedikt Gomez, Henning Reis, Georgios Stamatis, Hilmar Kühl, Verena Hartung,[...]. J Nucl Med 2014
77
3


PET imaging of estrogen receptors as a diagnostic tool for breast cancer patients presenting with a clinical dilemma.
Michel van Kruchten, Andor W J M Glaudemans, Erik F J de Vries, Regina G H Beets-Tan, Carolien P Schröder, Rudi A Dierckx, Elisabeth G E de Vries, Geke A P Hospers. J Nucl Med 2012
102
3

Surfing the p53 network.
B Vogelstein, D Lane, A J Levine. Nature 2000
3


Human breast cancer: correlation of relapse and survival with amplification of the HER-2/neu oncogene.
D J Slamon, G M Clark, S G Wong, W J Levin, A Ullrich, W L McGuire. Science 1987
3

Monitoring primary systemic therapy of large and locally advanced breast cancer by using sequential positron emission tomography imaging with [18F]fluorodeoxyglucose.
Jörg Schwarz-Dose, Michael Untch, Reinhold Tiling, Stefanie Sassen, Sven Mahner, Steffen Kahlert, Nadia Harbeck, Annette Lebeau, Winfried Brenner, Markus Schwaiger,[...]. J Clin Oncol 2009
157
3

Breast cancer with low FDG uptake: characterization by means of dual-time point FDG-PET/CT.
Ashraf Anas Zytoon, Koji Murakami, Mohamed Ramdan El-Kholy, Emad El-Shorbagy, Osama Ebied. Eur J Radiol 2009
26
11

Effects of noise, image resolution, and ROI definition on the accuracy of standard uptake values: a simulation study.
Ronald Boellaard, Nanda C Krak, Otto S Hoekstra, Adriaan A Lammertsma. J Nucl Med 2004
464
3

Comparison of Whole-Body (18)F FDG PET/MR Imaging and Whole-Body (18)F FDG PET/CT in Terms of Lesion Detection and Radiation Dose in Patients with Breast Cancer.
Amy N Melsaether, Roy A Raad, Akshat C Pujara, Fabio D Ponzo, Kristine M Pysarenko, Komal Jhaveri, James S Babb, Eric E Sigmund, Sungheon G Kim, Linda A Moy. Radiology 2016
60
5

Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer.
F Crippa, R Agresti, E Seregni, M Greco, C Pascali, A Bogni, C Chiesa, V De Sanctis, V Delledonne, B Salvadori,[...]. J Nucl Med 1998
126
3

THE METABOLISM OF TUMORS IN THE BODY.
O Warburg, F Wind, E Negelein. J Gen Physiol 1927
3


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.